Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-01-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartfractionejectionmyocardialventricular
  Phrases that lowered it: participantstrialdifferentphysicalinterfere
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past termination rate: 9.2% (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 22.1% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 32756 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 5582 (lowers risk) · Drug's FDA history
• Minimum age: 19 (lowers risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 76 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.8% (raises risk) · Drug's FDA history
• Disease area, infectious disease: Yes (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer NCT02258659 · started 2014 · scored riskier than 98% of active trials completed
• Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer NCT04572100 · started 2020 · scored riskier than 72% of active trials completed
• Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) NCT02573493 · started 2016 · scored riskier than 96% of active trials completed
• De-Escalation Therapy for Human Papillomavirus Negative Disease NCT03944915 · started 2019 · scored riskier than 96% of active trials completed
• Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer NCT01932697 · started 2013 · scored riskier than 95% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.